Novartis AG’s generics arm, Sandoz Inc., could be getting closer to being able to launch a generic version of Allergan Plc’s blockbuster glaucoma drug Combigan.
A Dec. 22 nonprecedential ruling from the U.S. Court of Appeals for the Federal Circuit reversed a 2016 district court decision that blocked Sandoz from selling its proposed generic product until April 2022.
But don’t count Allergan out just yet. The still has several defensive moves up its sleeve to protect the lucrative Combigan franchise from generic competition.
Allergan plans to file petitions for rehearing of the appeals court decision and also has asserted a new Orange Book patent against Sandoz’s generic version of Combigan, the company told Bloomberg Law.
The Orange Book is a Food and Drug Administration listing of patents that branded drugmakers claim cover their products and is formally titled “Approved Drug Products with Therapeutic Equivalence Evaluations.”
The current federal district court’s injunction preventing final approval and launch of the Sandoz product isn’t likely to be lifted before the appeals court decides whether to rehear the case, Allergan said.
In addition, because Allergan is suing Sandoz over a different Combigan patent in federal district court in New Jersey and that case has yet to be decided, Allergan said, it doesn’t believe the appeals court ruling will “result in the market formation for a generic Combigan product.”
Allergan Plc is headquartered in Dublin. Novartis AG, which owns Princeton, N.J.-based Sandoz, is based in Basel, Switzerland.
The case is Allergan Sales, LLC v. Sandoz, Inc., Fed. Cir., No. 17-1499, nonprecedential 12/22/17.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)